Trials / Conditions / Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

19 registered clinical trials studyying Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405	M.D. Anderson Cancer Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Active Not Recruiting	Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277	City of Hope Medical Center	Phase 2
Withdrawn	Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344	City of Hope Medical Center	Phase 2
Active Not Recruiting	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Posit NCT03147612	M.D. Anderson Cancer Center	Phase 2
Terminated	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486	Roswell Park Cancer Institute	Phase 2
Recruiting	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572	M.D. Anderson Cancer Center	Phase 2
Completed	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782	M.D. Anderson Cancer Center	Phase 2
Recruiting	Personalized NK Cell Therapy in CBT NCT02727803	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933	City of Hope Medical Center	Phase 2
Completed	Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134	City of Hope Medical Center	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Completed	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740	Fred Hutchinson Cancer Center	Phase 2
Completed	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Unknown	NK Cells in Cord Blood Transplantation NCT01619761	M.D. Anderson Cancer Center	Phase 1
Completed	Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Re NCT01428635	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Active Not Recruiting	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia NCT01424982	M.D. Anderson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2